Insights
Search Results
Client Highlights
6.27.25
Firm Advises ArrePath on IP Matters Related to Financing Round
On June 23, 2025, ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced that it has raised a new round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor’easter Ventures, and new investor AB Magnitude. Wilson Sonsini Goodrich & Rosati advised ArrePath on IP matters related to the transaction.
Client Highlights
1.09.25
Wilson Sonsini Advises General Atlantic on IP Matters Related to Verdiva Bio’s Formation and $410 Million Series A
On January 9, 2025, Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. Verdiva launched with an oversubscribed Series A financing of $411 million, co-led by General Atlantic and Forbion, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital (collectively, “the Investor Group”). Wilson Sonsini Goodrich & Rosati advised General Atlantic on IP matters related to Verdiva’s formation and Series A funding round.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Client Highlights
10.01.24
Wilson Sonsini Advises 858 Therapeutics on IP Matters Related to $50 Million Series B
On September 26, 2024, San Diego-based 858 Therapeutics, a biotechnology and drug discovery company developing a portfolio of small molecule therapeutics directed against novel oncology and immunology targets, announced the completion of a $50 million Series B financing led by Avidity Partners with participation from Insight Partners, Mirae Asset Capital, and Alexandria Venture Investments, as well as existing investors Versant Ventures, NEA, and Logos Capital. Wilson Sonsini Goodrich & Rosati advised 858 Therapeutics on intellectual property matters related to the transaction.
Client Highlights
4.03.24
Wilson Sonsini Advises Alterome on $132 Million Series B
On April 3, 2024, Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing. The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. Wilson Sonsini Goodrich & Rosati advised Alterome on the transaction.
Client Highlights
2.20.24
Wilson Sonsini Advises Kinnate Biopharma on Acquisition By XOMA
On February 16, 2024, Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate. Pursuant and subject to the terms of the merger agreement, a wholly owned subsidiary of XOMA will commence a tender offer by March 4, 2024 to acquire all outstanding shares of Kinnate common stock. The merger transaction is expected to close in the first half of 2024. Wilson Sonsini Goodrich & Rosati is advising Kinnate on the transaction.
Client Highlights
11.09.23
Wilson Sonsini Advises Forward Therapeutics on IP Matters Related to $50M Series A Financing
On November 8, 2023, Forward Therapeutics, a biopharmaceutical company developing small molecule therapies for chronic immunological and inflammatory disorders, announced that it raised $50 million in Series A funding. Wilson Sonsini Goodrich & Rosati advised Forward Therapeutics on IP matters related to the transaction.
Client Highlights
1.20.21
Wilson Sonsini Represents Kinnate Biopharma in $276 Million IPO
On December 7, 2020, Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of its initial public offering, raising $276 million. The shares began trading on The Nasdaq Global Select Market on December 3, 2020, under the symbol “KNTE.” All shares were offered by Kinnate.
Client Highlights
10.26.20
Wilson Sonsini Advises Azura Ophthalmics on IP Matters Related to $20 Million Financing
On October 22, 2020, Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, announced a $20 million financing. The round was led by a syndicate of existing investors, including OrbiMed, TPG Biotech, Brandon Capital’s Medical Research Commercialization Fund, and Ganot Capital. Wilson Sonsini advised Azura on intellectual property matters, including patents, related to this transaction.
Client Highlights
9.30.20
Wilson Sonsini Advises LifeSci Acquisition Corp. on IP Matters Related to Acquisition of Vincera Pharma
On September 29, 2020, LifeSci Acquisition Corp. (LSAC), a blank check company targeting the biopharma, medical technology, digital health, and healthcare services sectors and Vincera Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, announced that they have entered into a definitive agreement for a business combination.